Dazdotuftide

N/A

Report date: 2023/08/29 16:37:04
NME

Base Information

Drug NameDazdotuftide
Drug Alias NameTRS-01
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionNuclear factor NF-kappa-B complex inhibitorsMacrophages inhibitors
TargetsNuclear factor NF-kappa-B complex
Therapy Area/IndicationsOcular inflammationUveitis, AnteriorUveitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyFrance
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTarsius Pharma
China Registration ClassN/A

Develop Information

Active CompaniesTarsier Pharma Ltd
Inactive CompaniesN/A
Active IndicationsUveitis, AnteriorUveitisGlaucoma
Inactive IndicationsOcular inflammation

Other Information

ATC CodeN/A
Related LinksN/A